-
1
Transport of Alzheimer's associated amyloid-β catalyzed by P-glycoprotein.
Published 2021-01-01“…However, previous studies on the ability of P-gp to directly transport the Alzheimer's associated amyloid-β (Aβ) protein have produced contradictory results. …”
Get full text
Article -
2
-
3
Chronic neuropsychiatric sequelae of SARS‐CoV‐2: Protocol and methods from the Alzheimer's Association Global Consortium
Published 2022-01-01“…Discussion The Alzheimer's Association Global Consortium harmonized methodology is proposed as a model to study long‐term neurocognitive sequelae of SARS‐CoV‐2 infection. …”
Get full text
Article -
4
Relationship between Urinary Alzheimer-Associated Neuronal Thread Protein and Apolipoprotein Epsilon 4 Allele in the Cognitively Normal Population
Published 2020-01-01“…We investigated the relationship between urinary Alzheimer-associated neuronal thread protein (AD7c-NTP) levels and apolipoprotein epsilon 4 (ApoE ɛ4) alleles, as well as other factors that cause cognitive decline, in the cognitively normal population. …”
Get full text
Article -
5
The role of dyadic cognitive report and subjective cognitive decline in early ADRD clinical research and trials: Current knowledge, gaps, and recommendations
Published 2022-01-01“…The Subjective Cognitive Decline Professional Interest Area within the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment convened a working group focused on dyadic patterns of subjective report. …”
Get full text
Article -
6
Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice
Published 2024-10-01“…Abstract The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the Alzheimer's Association (AA) Workgroup represent a significant milestone in the field. …”
Get full text
Article -
7
-
8
Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease
Published 2024-10-01“…Highlights The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry, academia, and government to review the current state of non‐beta amyloid and non‐tau (NANT) targets on underlying Alzheimer's disease (AD) pathophysiology. …”
Get full text
Article -
9
Alzheimer's disease drug development in an evolving therapeutic landscape
Published 2024-10-01“…Highlights The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry and academia, as well as patients, clinicians, and government and regulatory agency scientists to discuss the topic, “Alzheimer's Disease Drug Development in an Evolving Therapeutic Landscape.” …”
Get full text
Article -
10
Alzheimer's disease: part 2 – the present
Published 2024-06-01“…Recently, new diagnostic criteria for AD were presented by the Alzheimer's Association, causing controversy about their use in clinical practice.…”
Get full text
Article -
11
Person‐centered assessment of apathy and resistance to care in people living with dementia: Review of existing measures
Published 2022-01-01“…Abstract Introduction The review described in this paper builds upon the Dementia Care Practice Recommendations (DCPR) published by the Alzheimer's Association in 2018 and addresses behavior change and the need for targeted outcome measures that evolve from person‐centered frameworks and help evaluate interventions. …”
Get full text
Article -
12
-
13
Hypothalamic volume is associated with age, sex and cognitive function across lifespan: a comparative analysis of two large population-based cohort studiesResearch in context
Published 2025-01-01“…Funding: Institutional funds, Federal Ministry of Education and Research of Germany, Alzheimer's Association.…”
Get full text
Article -
14
The Effectiveness of Motor Imagery in Balance and Functional Status of Older People with Early-Stage Dementia
Published 2024-11-01“…Methods: Overall, 160 participants (43 men, 117 women, MMSE M = 23.20, SD = 0.15) from an Athens Day Care Center of the Alzheimer Association were randomized to (a) the MI and exercise group (experimental group) (n = 55), (b) the only exercise group (1st control group) (n = 52) and (c) the neither MI nor exercise group (2nd control group) (n = 53). …”
Get full text
Article -
15
Cerebrospinal Fluid Classical Biomarker Levels in Mixed vs. Pure A<sup>+</sup>T<sup>+</sup> (A<sup>+</sup>T<sub>1</sub><sup>+</sup>) Alzheimer’s Disease
Published 2024-12-01“…<b>Methods</b>: Classical CSF AD biomarkers were determined in a total of 61 patients, classified as both beta amyloid- and tau-positive A<sup>+</sup>T<sup>+</sup> (or A<sup>+</sup>T<sub>1</sub><sup>+</sup> according to the recently revised Alzheimer Association criteria for diagnosis and staging of AD). …”
Get full text
Article -
16
Effects of Mental Imagery on Quality of Life, Cognitive, and Emotional Status in Older Adults with Early-Stage Alzheimer’s Disease Dementia: A Randomized Controlled Trial
Published 2024-12-01“…The sample from an Athens Day Care Center of the Alzheimer Association was randomized to (a) the MI and exercise group (intervention group, n = 55), (b) the only exercise group (1st control group, n = 52), and (c) the neither MI nor exercise group (2nd control group, n = 53). …”
Get full text
Article -
17
Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges
Published 2024-12-01“…The National Institute on Aging and the Alzheimer's Association have updated diagnostic criteria to include biomarker data, enhancing early diagnosis.ConclusionThe management of AD includes pharmacological treatments, such as cholinesterase inhibitors and NMDA receptor antagonists, which provide symptomatic relief but do not slow disease progression. …”
Get full text
Article -
18
-
19
Identification of late-stage tau accumulation using plasma phospho-tau217Research in context
Published 2024-11-01“…Funding: This research is supported by the Weston Brain Institute, Canadian Institutes of Health Research (CIHR) [MOP-11-51-31; RFN 152985, 159815, 162303], Canadian Consortium of Neurodegeneration and Aging (CCNA; MOP-11-51-31 -team 1), the Alzheimer's Association [NIRG-12-92090, NIRP-12-259245], Brain Canada Foundation (CFI Project 34874; 33397), the Fonds de Recherche du Québec—Santé (FRQS; Chercheur Boursier, 2020-VICO-279314). …”
Get full text
Article